Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.
Authors
Geoffrey Yuyat Ku
Memorial Sloan Kettering Cancer Center, New York, NY
Geoffrey Yuyat Ku , Abraham Jing-Ching Wu , Nikhil Trivedi , Steven Brad Maron , Smita Suhas Joshi , David H. Ilson , Yelena Y. Janjigian , Marina Shcherba , Jia Li , Laura H. Tang , Randy Yeh , Smita Sihag , Bernard J. Park , David Randolph Jones , Daniela Molena
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02962063
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 355)
DOI
10.1200/JCO.2024.42.3_suppl.355
Abstract #
355
Poster Bd #
G16
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.
First Author: Darren Cowzer
Poster
2020 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
First Author: Michele Ly
Poster
2021 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
First Author: Geoffrey Yuyat Ku
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang